Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Teva Pharma increases potential Copaxone generic competition impact; call underway (32.19)<p>FY17 guidance assumes no generic Copaxone competition — potential impact of 1-2 generic competitors to Copaxone 40 mg launching in Feb 17 in the U.S: Revenues decrease $1.0 — $1.3 billion (from 1.0-1.2 bln); EPS decrease $0.75 — $0.95 (up from $0.65-0.80).</p><p>Q1 will be the lowest of the four quarters; 40% of 2017 EPS will be generated in Q1-Q2; 60% in Q3-Q4; majority of U.S. Gx launches expected only in the second half of 2017</p><p>Copaxone accounted for 36% of profit in Q4</p></td> </tr></table>"